Colony Group LLC Buys Shares of 4,394 Sanofi SA (NYSE:SNY)

Posted by Grant Hamersma on Dec 3rd, 2019

Colony Group LLC bought a new stake in Sanofi SA (NYSE:SNY) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 4,394 shares of the company’s stock, valued at approximately $204,000.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Flagship Harbor Advisors LLC boosted its stake in shares of Sanofi by 30.2% in the second quarter. Flagship Harbor Advisors LLC now owns 1,380 shares of the company’s stock worth $59,000 after acquiring an additional 320 shares during the period. AE Wealth Management LLC boosted its stake in shares of Sanofi by 26.9% in the second quarter. AE Wealth Management LLC now owns 6,057 shares of the company’s stock worth $262,000 after acquiring an additional 1,284 shares during the period. Commerzbank Aktiengesellschaft FI boosted its stake in shares of Sanofi by 13.4% in the second quarter. Commerzbank Aktiengesellschaft FI now owns 30,620 shares of the company’s stock worth $1,325,000 after acquiring an additional 3,609 shares during the period. Logan Capital Management Inc. boosted its stake in shares of Sanofi by 11.5% in the second quarter. Logan Capital Management Inc. now owns 29,452 shares of the company’s stock worth $1,274,000 after acquiring an additional 3,047 shares during the period. Finally, Greenleaf Trust boosted its stake in shares of Sanofi by 16.6% in the second quarter. Greenleaf Trust now owns 16,542 shares of the company’s stock worth $716,000 after acquiring an additional 2,358 shares during the period. 7.04% of the stock is currently owned by institutional investors.

In related news, major shareholder Sanofi sold 172,904 shares of the stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $281.15, for a total transaction of $48,611,959.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 1.00% of the stock is currently owned by corporate insiders.

A number of equities analysts have recently weighed in on the company. Jefferies Financial Group reaffirmed a “buy” rating on shares of Sanofi in a research note on Thursday, August 29th. Argus reaffirmed a “buy” rating and issued a $52.00 price objective (up previously from $50.00) on shares of Sanofi in a research note on Wednesday, November 13th. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Sanofi in a research note on Monday, October 14th. Morgan Stanley raised Sanofi from an “equal” rating to a “weight” rating in a research note on Friday, September 20th. Finally, UBS Group raised Sanofi from a “neutral” rating to a “buy” rating in a research note on Wednesday, August 14th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $50.33.

Shares of Sanofi stock opened at $45.82 on Tuesday. The stock has a 50 day moving average of $46.10 and a 200 day moving average of $43.85. Sanofi SA has a 12 month low of $40.00 and a 12 month high of $47.47. The firm has a market cap of $116.89 billion, a PE ratio of 14.64, a PEG ratio of 2.41 and a beta of 0.67. The company has a current ratio of 1.22, a quick ratio of 0.85 and a debt-to-equity ratio of 0.40.

Sanofi (NYSE:SNY) last announced its quarterly earnings results on Thursday, October 31st. The company reported $1.07 EPS for the quarter, beating analysts’ consensus estimates of $0.96 by $0.11. Sanofi had a return on equity of 18.18% and a net margin of 12.20%. The company had revenue of $10.56 billion during the quarter, compared to analyst estimates of $10.62 billion. As a group, equities research analysts forecast that Sanofi SA will post 3.1 earnings per share for the current fiscal year.

Sanofi Profile

Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.